A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments.
Latest Information Update: 21 Nov 2022
At a glance
- Drugs CV 8102 (Primary) ; HepaVac 101 (Primary) ; Cyclophosphamide
- Indications Carcinoma; Liver cancer
- Focus Adverse reactions; First in man; Pharmacodynamics
- Acronyms HepaVac101
- 14 Apr 2022 Results published in the Clinical Cancer Research
- 26 Jun 2021 Results presented at The International Liver Congress 2021
- 29 Aug 2020 Results presented at The International Liver Congress 2020